Yunlong Cui

机构：Tianjin Medical University Cancer Institute and Hospital · ORCID：0000-0001-7489-4041

发表论文 87 篇 · 总被引 1513 次 · h-index 21

代表论文

• Mitochondrial GCN5L1 regulates glutaminase acetylation and hepatocellular carcinoma (2022 · Clinical and Translational Medicine · 被引 34)
• A Retrospective Analysis of Conversion Therapy with Lenvatinib, Sintilimab, and Arterially-Directed Therapy in Patients with Initially Unresectable Hepatocellular Carcinoma (2023 · Journal of Hepatocellular Carcinoma · 被引 25)
• Elevated serum CA19-9 indicates severe liver inflammation and worse survival after curative resection in hepatitis B-related hepatocellular carcinoma (2021 · BioScience Trends · 被引 23)
• Identification of a seven-gene signature predicting clinical outcome of liver cancer based on tumor mutational burden (2022 · Human Cell · 被引 15)
• Efficacy and safety of sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a two-center study in China (2022 · Journal of Gastrointestinal Oncology · 被引 13)
• CDCA8 Facilitates Tumor Proliferation and Predicts a Poor Prognosis in Hepatocellular Carcinoma (2023 · Applied Biochemistry and Biotechnology · 被引 11)